Palatin Technologies Incorporated

Therapeuticsmd, Inc.

Annette M Shadiack

Shubh D Sharma

Ramesh Rajpurohit

Yi-Qun Shi

Kevin D Burris

Peter H R Persicaner

Wei Yang

Thorsteinn Thorsteinsson

Jason D Legassie

Frederick D Sancilio

Zhijun Wu

Papireddy Purma

Philip B Inskeep

Christine H Blood

Joanna K Bernstein

Guy H Herbert

Julia M Amadio

Hui-Zhi Cai

Richard Winneker

Carl Spana

Lisa E Diamond

Yiqun Shi

Dennis C Earle

Ajay Ghanta

Veeran Gowda Kadajji

Mafruhul Bari

This disclosure provides pharmaceutical compositions for delivering estradiol to a subject in need thereof, as well as methods of administering the compositions, and methods of using them.

Steroid hormone pharmaceutical formulations

This disclosure provides a novel pharmaceutical composition for delivering steroid hormones to a patient in need thereof.

Steroid hormone pharmaceutical composition

This disclosure provides a novel pharmaceutical composition capable of forming micelles upon exposure to the gastric environment. The pharmaceutical composition is suitable for delivering steroid hormones, and progesterone in particular, to a subject in need thereof.

Steroid hormone compositions in medium chain oils

This disclosure relates to transdermal pharmaceutical compositions containing progesterone in combination with one or more solubilizing agents and penetration enhancers, wherein the pharmaceutical compositions are formulated as creams for topical administration. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, and d-limonene. In some embodiments, the transdermal pharmaceutical compositions contain progesterone, a medium-chain oil, a penetration enhancer (e.g., propylene glycol, a fatty acid ester of propylene glycol, a glycol ether), and optionally d-limonene. In certain embodiments, the pharmaceutical compositions further include estradiol. Methods for treating conditions associated with hormone deficiency in a subject are also described.

Transdermal cream

A melanocortin-4 receptor agonist cyclic peptide of the formula where R, R, R, R, R, R, R, R, R, x, y and z are as defined in the specification, and a method of treating sexual dysfunction, including male erectile dysfunction and female sexual dysfunction, and other melanocortin 4 receptor responsive conditions and disorders.

N-alkylated cyclic peptide melanocortin agonists

A melanocortin receptor-specific compound of the general formula of structure I: where X, R, R, R, R, R, R, Rand Rare as defined in the specification, which compound binds with high affinity to one or more melanocortin receptors and is optionally an agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.

Melanocortin receptor-specific compounds

A peptide of the structural formula: or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, R, m and n are as defined. Further provided are methods for treatment of sexual dysfunction, including erectile dysfunction and female sexual dysfunction, and combination drugs and method of use thereof, including a peptide of the invention and one or more second sexual dysfunction pharmaceutical agents.

Peptide compositions for treatment of sexual dysfunction

A method of modulating energy homeostasis in a mammal without eliciting a sexual response by administration of a therapeutically effective amount of a pharmaceutical composition including a melanocortin receptor compound of the formula: where Ris a bond or a linker unit including from one to six backbone atoms and an unsubstituted naphthalene group, and L, R, Rand Rare as defined in the specification.

Naphthalene-containing melanocortin receptor-specific small molecule

Linear and cyclic peptides are provided specific to one or melanocortin receptors, and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. In one embodiment, a linear peptide of the following general formula is provided: 

Linear and cyclic melanocortin receptor-specific peptides

Metallopeptide compositions are provided for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction. The metallopeptides include at least one, and preferably two, aromatic amino acid side chain moieties, and are further characterized in that the metallopeptides preferably do not bind or significantly bind to a melanocortin receptor.

Metallopeptide compositions for treatment of sexual dysfunction

A highly selective melanocortin-4 receptor antagonist cyclic hexapeptide of the formula where R, R, R, R, R, R, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.

Cyclic peptides for treatment of cachexia

A highly selective melanocortin-4 receptor antagonist cyclic peptide of the formula where R, R, R, R, R, R, R, R, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.

Cyclic peptides for treatment for cachexia

Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.

Growing community of inventors

Sommerset, NJ, United States of America

Annette M Shadiack